Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 15, 2011

Evotec Expands Screening Library with Addition of 110,000 ChemBridge Compounds

  • Evotec says its screening library will be increased in size by nearly 50% through a collaboration with compound libraries firm ChemBridge. Through the agreement, Evotec will initially add 110,000 diverse lead-like compounds from the ChemBridge Library Collection to its existing library of 250,000 compounds. The firm says the new additions will complement the chemical diversity of its existing collection.

    “We are pleased to have this opportunity to work with Evotec,” comments Eugene Vaisberg, ChemBridge CEO. “This alliance will allow ChemBridge to expand the reach of its renowned small molecule screening library via Evotec’s industry-leading hit-identification platform.”

    Based in San Diego, ChemBridge is a specialist discovery chemistry company offering range of off-the-shelf and custom products and contract research services. The firm has screening compound libraries totaling over 700,000 diverse compounds and target focused compounds, 12,000 chemical building blocks, custom compound libraries, and synthetic and medicinal chemistry support services.

    ChemBridge’s discovery chemistry services operation is headed at its center in Moscow, and is focused primarily on bench-scale chemistry including the development of library scaffolds, intermediates, and building blocks.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »